Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cognition Therapeutics Q3 2026 Results: Net Loss of $4.14M, Loss Narrows

Cognition Therapeutics reported a decrease in cash and cash equivalents to $30.8 million as of September 30, 2026, compared to $36.8 million at year-end 2025. The company's accumulated deficit grew to $211.3 million, reflecting ongoing clinical development costs for its lead product candidate, zervimesine (CT1812).

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.1-4.9
EPS (diluted, $ a share)$-0.04$-0.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CGTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cognition Therapeutics Inc: key numbers

Share price
$0.6388Close, Nov 16
Market cap
$60.8M
Shares outstanding
95.1MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cognition Therapeutics Inc

All →
6:06 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Cognition Therapeutics Nasdaq/NYSE Compliance Notice

Cognition Therapeutics received a deficiency notice from Nasdaq on November 3, 2026, because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.

Counterparty
Nasdaq
Term
180 days

“The work we conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB). We are now evaluating our plans for manufacturing, site selection, and patient recruitment.”

Lisa Ricciardi, Cognition’s president and CEO

“At the same time, we are working with our collaborators at the Alzheimer’s Clinical Trial Consortium (ACTC) to prepare for the conclusion of the Phase 2 START Study in people with MCI and early Alzheimer’s disease. Top-line results from START are anticipated in the second half of 2027 and will inform our plans for zervimesine in Alzheimer’s disease.”

Lisa Ricciardi, Cognition’s president and CEO
6:06 AM ET 8-K
Business Update

Cognition Therapeutics Business Update

Cognition Therapeutics has reached alignment with the FDA on the design of its planned Phase 3 registrational study for zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). The study will focus on mild-to-moderate DLB patients using hallucinations (NPI-2) as a primary endpoint and daily function (ADCS-ADL) as a secondary endpoint.

Counterparty
FDA
Term
9 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.